GILD GoodMoat Verdict
Full signal breakdown coming soon. Use the X-Ray tool for a detailed analysis.
Gilead Sciences Inc
Exchange: NASDAQSector: HealthcareIndustry: Drug Manufacturers - General
For more than 35 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment, prevention and cure research. Gilead researchers have developed 13 HIV medications, including the first single-tablet regimen to treat HIV, the first antiretroviral for pre-exposure prophylaxis (PrEP) to help reduce new HIV infections, and the first long-acting injectable HIV treatment medication administered twice-yearly. Our advances in medical research have helped to transform HIV into a treatable, preventable, chronic condition for millions of people. Gilead is committed to continued scientific innovation to provide solutions for the evolving needs of people affected by HIV around the world. Through partnerships, collaborations and charitable giving, the company also aims to improve education, expand access and address barriers to care, with the goal of ending the HIV epidemic for everyone, everywhere. Gilead has been recognized as one of the leading philanthropic funders of HIV-related programs in a report released by Funders Concerned About AIDS. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.
Did you know?
Price sits at 65% of its 52-week range.
Current Price
$133.64
+0.56%GoodMoat Value
$120.02
10.2% overvaluedProfile
Valuation (TTM)
Market Cap$165.80B
P/E19.48
EV$187.70B
P/B7.30
Shares Out1.24B
P/Sales5.63
Revenue$29.44B
EV/EBITDA13.48
Gilead Sciences Inc (GILD) Quality Analysis
GoodMoat Analysis
Gilead Sciences exhibits strong profitability with high margins and exceptional returns on equity, but its quality profile is mixed. The business generates robust cash flow and is GAAP profitable, yet faces challenges with modest revenue growth and a leveraged balance sheet. Its competitive position is anchored in a portfolio of established, mission-critical drugs, creating high switching costs.
Read full analysis
Gilead Sciences demonstrates a strong core of profitability, a key focus for value investors. The company's operating margin of 34.0% and profit margin of 28.9% indicate efficient operations and pricing power. Most notably, its Return on Equity (ROE) of 37.5% far exceeds the framework's high-quality threshold of 15-20%, signaling exceptional returns on shareholder capital. Free cash flow generation is also robust, with a 5.5% FCF yield suggesting healthy cash conversion, though we lack the specific FCF margin to compare against the >10-15% benchmark. The business is firmly GAAP profitable. However, quality indicators are not uniformly strong. Revenue growth is modest at 4.7% YoY, which is not the consistent double-digit growth associated with high-quality compounders. The balance sheet shows leverage with a Debt/Equity ratio of 1.10, which is above the framework's preference for low/zero debt (Debt/EBITDA < 1.0x). Regarding competitive position (Moat Identification), Gilead likely scores on criteria like Switching Costs, as its antiviral and oncology treatments are often mission-critical for patients, and Regulatory Barriers, through its portfolio of patents and FDA approvals. This provides a durable, though not impenetrable, moat. Compared to biopharma peers, Gilead's profitability metrics are generally favourable, but its growth trajectory lags behind more innovative competitors. The quality is adequate but not outstanding, with strengths in current returns tempered by growth and leverage concerns. Analysis based on data as of 2024-05-15.
GILD Profitability
Profitability trend analysis coming soon
GILD Growth
Growth trend analysis coming soon
GILD Financial Health
Financial health indicators coming soon
GILD Quality & Fundamental Analysis
Gilead Sciences Inc (GILD) is a Healthcare company in the Drug Manufacturers - General industry, listed on NASDAQ. This quality analysis page evaluates Gilead Sciences Inc's financial health using the Piotroski F-Score methodology, profitability ratios, growth trajectory, and balance sheet strength.
Gilead Sciences Inc has a Piotroski F-Score of N/A out of 9, measuring profitability, leverage, and operating efficiency. The company operates with a profit margin of 28.90% and a return on equity (ROE) of 37.48%. Return on assets (ROA) stands at 14.42%.
The debt-to-equity ratio is 1.10, with a current ratio of 1.55. Operating margin is 34.04%.
GoodMoat's quality analysis uses AI-powered insights to evaluate whether Gilead Sciences Inc is a fundamentally sound investment. The GoodMoat Verdict synthesizes profitability, growth, and financial health scores into a clear investment quality rating. Use these metrics alongside valuation tools like the DCF calculator and fair value models to make informed investment decisions.